We are live on ! Find out more
KDNY

Chinook Therapeutics, Inc. Common Stock
KDNY

Delisted

KDNY was delisted on the 10th of August, 2023.

Back to rankings

2 hedge funds and large institutions have $0 invested in Chinook Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 181 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 185 → 2 (-183)

100% less funds holding in top 10

Funds holding in top 10: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $2.24B → $0 (-$2.24B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 181

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-183
Holders Change %
-98.92%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
181
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SB
Samsara BioCapital
California
-$198M
2
FLSM
Frazier Life Sciences Management
California
-$167M
3
BlackRock
BlackRock
New York
-$164M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$113M
5
State Street
State Street
Massachusetts
-$112M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
– -$22.6M -587,576 Closed
Hudson Bay Capital Management
27
Hudson Bay Capital Management
Connecticut
– -$22.1M -574,274 Closed
WCMNY
28
Westchester Capital Management (New York)
New York
– -$21.5M -559,062 Closed
Millennium Management
29
Millennium Management
New York
– -$21.2M -552,166 Closed
SVCM
30
Saturn V Capital Management
Texas
– -$20.2M -524,811 Closed
Goldman Sachs
31
Goldman Sachs
New York
– -$19.5M -508,062 Closed
PCM
32
Pentwater Capital Management
Florida
– -$17.9M -465,000 Closed
Baillie Gifford & Co
33
Baillie Gifford & Co
United Kingdom
– -$17.8M -463,945 Closed
HSBC Holdings
34
HSBC Holdings
United Kingdom
– -$17.1M -442,815 Closed
Morgan Stanley
35
Morgan Stanley
New York
– -$15.7M -408,746 Closed
SCM
36
Segantii Capital Management
Hong Kong
– -$15.4M -400,000 Closed
RSCM
37
Rock Springs Capital Management
Maryland
– -$15.2M -396,280 Closed
Charles Schwab
38
Charles Schwab
California
– -$14.4M -375,239 Closed
Ensign Peak Advisors
39
Ensign Peak Advisors
Utah
– -$13.8M -359,480 Closed
VI
40
Versor Investments
New York
– -$13.4M -348,543 Closed
AAA
41
Affinity Asset Advisors
New York
– -$12.3M -321,017 Closed
SGCM
42
Sand Grove Capital Management
United Kingdom
– -$12.1M -315,973 Closed
Bank of America
43
Bank of America
North Carolina
– -$11.8M -308,007 Closed
EAM
44
Erste Asset Management
Austria
– -$11.8M -307,769 Closed
ACM
45
Altium Capital Management
New York
– -$11.7M -305,000 Closed
JP Morgan Chase
46
JP Morgan Chase
New York
– -$10.9M -283,819 Closed
IC
47
Ikarian Capital
Texas
– -$130K -283,464 Closed
NAM
48
Nexpoint Asset Management
Texas
– -$10.9M -282,592 Closed
D.E. Shaw & Co
49
D.E. Shaw & Co
New York
– -$10.8M -282,154 Closed
KC
50
Kryger Capital
United Kingdom
– -$9.4M -244,657 Closed
1
2
3 4 5

KDNY Hedge Fund Activity: Q3 2023 in Review

2 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q3 2023, worth a combined $0 — down 100% from $2.24B a quarter earlier.

Sellers outnumbered buyers: 181 funds closed out of KDNY and 0 opened new positions — a net loss of 181 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Samsara BioCapital, exiting entirely with an estimated $198M sold.

  • 2 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q3 2023, down from 185 in Q2 2023.
  • Funds reported $0 of Chinook Therapeutics, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q3 2023 and 181 closed out, a net change of -181 holders.
  • The largest Chinook Therapeutics, Inc. Common Stock seller in Q3 2023 was Samsara BioCapital, an estimated $198M sold.

Based on aggregated 13F filings for Q3 2023.